<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7758046\results\search\disease\results.xml">
  <result pre="to evaluate their antiproliferative activity inÂ vitro against 60 human" exact="cancer" post="cells lines. Preliminary screening of the examined compounds indicated"/>
  <result pre="health problem characterised by uncontrolled growth of abnormal cells. Although" exact="cancer" post="research resulted in a range of innovative and promising"/>
  <result pre="approaches, the medications used as therapies have strong drawbacks and" exact="cancer" post="is expected to be the leading cause of death"/>
  <result pre="be the leading cause of death in the future1â€&quot;3. Targeted" exact="cancer" post="treatments have recently been approved to treat specific cancers"/>
  <result pre="potential inhibitory activity of VEGFR could be considered as important" exact="cancer" post="prevention targets54â€&quot;56. Figure 1. Examples of chalcones, pyrazoles, and"/>
  <result pre="compounds were selected by NCI, and 60 lines of human" exact="cancer" post="cells were screened inÂ vitro. The inhibitory activity had"/>
  <result pre="showed moderate to good inhibitory activity mainly against leukaemia and" exact="colon cancer" post="cell lines. Table 1. In vitro growth inhibitory percent"/>
  <result pre="moderate to good inhibitory activity mainly against leukaemia and colon" exact="cancer" post="cell lines. Table 1. In vitro growth inhibitory percent"/>
  <result pre="and VIc at 10Â ÂµM concentration, towards the 60 subpanel" exact="cancer" post="cell lines, results were given as a percentage of"/>
  <result pre="92.51 SR 55.72 46.22 92.99 94.43 67.42 90.38 Non-small cell" exact="lung cancer" post="A549/ATCC 76.84 67.25 78.75 78.06 68.21 76.20 EKVX 95.54"/>
  <result pre="SR 55.72 46.22 92.99 94.43 67.42 90.38 Non-small cell lung" exact="cancer" post="A549/ATCC 76.84 67.25 78.75 78.06 68.21 76.20 EKVX 95.54"/>
  <result pre="95.16 94.92 NCI-H522 71.57 61.19 78.82 69.51 66.27 81.93 Colon" exact="cancer" post="COLO 205 96.91 83.00 111.89 113.04 93.87 95.69 HCC-2998"/>
  <result pre="93.81 96.23 SW-620 61.08 50.69 105.59 94.11 91.67 93.46 CNS" exact="cancer" post="SF-268 85.41 94.03 100.92 100.24 93.72 107.32 SF-295 101.78"/>
  <result pre="80.93 83.07 UACC-62 79.23 80.13 92.01 88.47 86.00 81.93 Ovarian" exact="cancer" post="IGROV1 67.97 59.94 97.17 93.22 82.04 67.96 OVCAR-3 93.74"/>
  <result pre="104.69 106.03 SK-OV-3 79.98 87.98 96.68 96.47 83.58 85.00 Renal" exact="cancer" post="786-0 85.24 87.22 103.38 106.73 94.50 111.09 A498 95.14"/>
  <result pre="113.60 122.80 UO-31 76.58 58.35 89.78 86.28 76.56 77.18 Prostate" exact="cancer" post="PC-3 66.01 51.40 73.56 83.35 64.23 70.34 DU-145 77.70"/>
  <result pre="64.23 70.34 DU-145 77.70 105.61 108.14 104.00 103.62 107.16 Breast" exact="cancer" post="MCF7 51.72 34.68 99.38 93.05 68.65 73.03 MDA-MB-231/ATCC 73.60"/>
  <result pre="bearing 3-fluoropyridine moiety showed weak anti-proliferative activity against non-small cell" exact="lung cancer" post="HOP-92, leukaemia K-562, colon cancer HT29, leukaemia SR, and"/>
  <result pre="3-fluoropyridine moiety showed weak anti-proliferative activity against non-small cell lung" exact="cancer" post="HOP-92, leukaemia K-562, colon cancer HT29, leukaemia SR, and"/>
  <result pre="anti-proliferative activity against non-small cell lung cancer HOP-92, leukaemia K-562," exact="colon cancer" post="HT29, leukaemia SR, and breast cancer MCF7 cancer cell"/>
  <result pre="activity against non-small cell lung cancer HOP-92, leukaemia K-562, colon" exact="cancer" post="HT29, leukaemia SR, and breast cancer MCF7 cancer cell"/>
  <result pre="cancer HOP-92, leukaemia K-562, colon cancer HT29, leukaemia SR, and" exact="breast cancer" post="MCF7 cancer cell lines, with cell growth promotion (82.34%,"/>
  <result pre="HOP-92, leukaemia K-562, colon cancer HT29, leukaemia SR, and breast" exact="cancer" post="MCF7 cancer cell lines, with cell growth promotion (82.34%,"/>
  <result pre="K-562, colon cancer HT29, leukaemia SR, and breast cancer MCF7" exact="cancer" post="cell lines, with cell growth promotion (82.34%, 85.84%, 86.42%,"/>
  <result pre="inhibition: 20.72%), leukaemia CCRF-CEM (78.16%; cell growth inhibition: 21.84%), and" exact="colon cancer" post="HCT-116 (cell growth promotion 73.87%; cell growth inhibition: 26.13%)."/>
  <result pre="20.72%), leukaemia CCRF-CEM (78.16%; cell growth inhibition: 21.84%), and colon" exact="cancer" post="HCT-116 (cell growth promotion 73.87%; cell growth inhibition: 26.13%)."/>
  <result pre="moiety, compound Vd significantly increased growth inhibition against number of" exact="cancer" post="cell lines, such as leukaemia HL-60(TB), non-small cell lung"/>
  <result pre="of cancer cell lines, such as leukaemia HL-60(TB), non-small cell" exact="lung cancer" post="HOP-92, leukaemia CCRF-CEM, leukaemia SR, and breast cancer MCF7"/>
  <result pre="cancer cell lines, such as leukaemia HL-60(TB), non-small cell lung" exact="cancer" post="HOP-92, leukaemia CCRF-CEM, leukaemia SR, and breast cancer MCF7"/>
  <result pre="non-small cell lung cancer HOP-92, leukaemia CCRF-CEM, leukaemia SR, and" exact="breast cancer" post="MCF7 with percent growth inhibition of 39.17%, 41.59%, 41.82%,"/>
  <result pre="cell lung cancer HOP-92, leukaemia CCRF-CEM, leukaemia SR, and breast" exact="cancer" post="MCF7 with percent growth inhibition of 39.17%, 41.59%, 41.82%,"/>
  <result pre="In addition, compound Vd, showed good to excellent activity against" exact="colon cancer" post="HCT-116, colon cancer HT29, and leukaemia K-562 with percent"/>
  <result pre="addition, compound Vd, showed good to excellent activity against colon" exact="cancer" post="HCT-116, colon cancer HT29, and leukaemia K-562 with percent"/>
  <result pre="Vd, showed good to excellent activity against colon cancer HCT-116," exact="colon cancer" post="HT29, and leukaemia K-562 with percent growth inhibition of"/>
  <result pre="showed good to excellent activity against colon cancer HCT-116, colon" exact="cancer" post="HT29, and leukaemia K-562 with percent growth inhibition of"/>
  <result pre="4-fluoro-3-methoxyphenyl moiety compound Ve markedly increase growth inhibition towards many" exact="cancer" post="cell lines. It showed cell growth promotion for non-small"/>
  <result pre="cell lines. It showed cell growth promotion for non-small cell" exact="lung cancer" post="HOP-92 (55.00%; cell growth inhibition: 45.00%), leukaemia SR (46.22%;"/>
  <result pre="lines. It showed cell growth promotion for non-small cell lung" exact="cancer" post="HOP-92 (55.00%; cell growth inhibition: 45.00%), leukaemia SR (46.22%;"/>
  <result pre="growth inhibition: 45.00%), leukaemia SR (46.22%; cell growth inhibition: 53.78%)," exact="breast cancer" post="MCF7 (34.68%; cell growth inhibition: 65.32%), leukaemia HL-60(TB) (28.91%;"/>
  <result pre="inhibition: 45.00%), leukaemia SR (46.22%; cell growth inhibition: 53.78%), breast" exact="cancer" post="MCF7 (34.68%; cell growth inhibition: 65.32%), leukaemia HL-60(TB) (28.91%;"/>
  <result pre="growth inhibition: 65.32%), leukaemia HL-60(TB) (28.91%; cell growth inhibition: 71.09%)," exact="colon cancer" post="HCT-116 (27.43%; cell growth inhibition: 72.57%), leukaemia CCRF-CEM (22.15%;"/>
  <result pre="inhibition: 65.32%), leukaemia HL-60(TB) (28.91%; cell growth inhibition: 71.09%), colon" exact="cancer" post="HCT-116 (27.43%; cell growth inhibition: 72.57%), leukaemia CCRF-CEM (22.15%;"/>
  <result pre="leukaemia CCRF-CEM, leukaemia HL-60(TB), leukaemia K-562, leukaemia SR non-small cell" exact="lung cancer" post="HOP-92, colon cancer HCT-116, and breast cancer MCF7 cell"/>
  <result pre="CCRF-CEM, leukaemia HL-60(TB), leukaemia K-562, leukaemia SR non-small cell lung" exact="cancer" post="HOP-92, colon cancer HCT-116, and breast cancer MCF7 cell"/>
  <result pre="HL-60(TB), leukaemia K-562, leukaemia SR non-small cell lung cancer HOP-92," exact="colon cancer" post="HCT-116, and breast cancer MCF7 cell lines. On the"/>
  <result pre="leukaemia K-562, leukaemia SR non-small cell lung cancer HOP-92, colon" exact="cancer" post="HCT-116, and breast cancer MCF7 cell lines. On the"/>
  <result pre="SR non-small cell lung cancer HOP-92, colon cancer HCT-116, and" exact="breast cancer" post="MCF7 cell lines. On the other hand, pyrazole analogues"/>
  <result pre="non-small cell lung cancer HOP-92, colon cancer HCT-116, and breast" exact="cancer" post="MCF7 cell lines. On the other hand, pyrazole analogues"/>
  <result pre="VIb, and VIc showed promising cytotoxicity towards a variety of" exact="cancer" post="cell lines. Compound VIa bearing benzonitrile moiety exhibited a"/>
  <result pre="bearing benzonitrile moiety exhibited a weak growth inhibition against several" exact="cancer" post="cell lines as it displayed cell growth promotion for"/>
  <result pre="growth promotion for leukaemia SR (94.43%; cell growth inhibition: 5.57%)," exact="colon cancer" post="HT29 (87.83%; cell growth inhibition: 12.17%), colon cancer HCT-116"/>
  <result pre="promotion for leukaemia SR (94.43%; cell growth inhibition: 5.57%), colon" exact="cancer" post="HT29 (87.83%; cell growth inhibition: 12.17%), colon cancer HCT-116"/>
  <result pre="inhibition: 5.57%), colon cancer HT29 (87.83%; cell growth inhibition: 12.17%)," exact="colon cancer" post="HCT-116 (85.83%; cell growth inhibition: 14.17%), and non-small cell"/>
  <result pre="5.57%), colon cancer HT29 (87.83%; cell growth inhibition: 12.17%), colon" exact="cancer" post="HCT-116 (85.83%; cell growth inhibition: 14.17%), and non-small cell"/>
  <result pre="cancer HCT-116 (85.83%; cell growth inhibition: 14.17%), and non-small cell" exact="lung cancer" post="HOP-92 (83.18%; cell growth inhibition: 16.82%). In addition, it"/>
  <result pre="HCT-116 (85.83%; cell growth inhibition: 14.17%), and non-small cell lung" exact="cancer" post="HOP-92 (83.18%; cell growth inhibition: 16.82%). In addition, it"/>
  <result pre="16.82%). In addition, it showed good inhibitory activity against many" exact="cancer" post="cell lines with cell growth promotion for leukaemia K-562"/>
  <result pre="for leukaemia K-562 (78.12%; cell growth inhibition: 21.88%), non-small cell" exact="lung cancer" post="A549/ATCC (78.06%; cell growth inhibition: 21.94%), leukaemia CCRF-CEM (71.21%;"/>
  <result pre="leukaemia K-562 (78.12%; cell growth inhibition: 21.88%), non-small cell lung" exact="cancer" post="A549/ATCC (78.06%; cell growth inhibition: 21.94%), leukaemia CCRF-CEM (71.21%;"/>
  <result pre="leukaemia CCRF-CEM (71.21%; cell growth inhibition: 28.79%), and non-small cell" exact="lung cancer" post="NCI-H522 (69.51%; cell growth inhibition: 30.49%). Replacing benzonitrile moiety"/>
  <result pre="CCRF-CEM (71.21%; cell growth inhibition: 28.79%), and non-small cell lung" exact="cancer" post="NCI-H522 (69.51%; cell growth inhibition: 30.49%). Replacing benzonitrile moiety"/>
  <result pre="with 3-fluoropyridine moiety, compound VIc increased anti-proliferative activity against few" exact="cancer" post="cell lines such as colon cancer HCT-116, non-small cell"/>
  <result pre="increased anti-proliferative activity against few cancer cell lines such as" exact="colon cancer" post="HCT-116, non-small cell lung cancer HOP-92 and colon cancer"/>
  <result pre="anti-proliferative activity against few cancer cell lines such as colon" exact="cancer" post="HCT-116, non-small cell lung cancer HOP-92 and colon cancer"/>
  <result pre="cancer cell lines such as colon cancer HCT-116, non-small cell" exact="lung cancer" post="HOP-92 and colon cancer HT29 with percent of cell"/>
  <result pre="cell lines such as colon cancer HCT-116, non-small cell lung" exact="cancer" post="HOP-92 and colon cancer HT29 with percent of cell"/>
  <result pre="as colon cancer HCT-116, non-small cell lung cancer HOP-92 and" exact="colon cancer" post="HT29 with percent of cell growth inhibition of 26.18%,"/>
  <result pre="colon cancer HCT-116, non-small cell lung cancer HOP-92 and colon" exact="cancer" post="HT29 with percent of cell growth inhibition of 26.18%,"/>
  <result pre="derivative and exhibited moderate to good inhibitory activity towards many" exact="cancer" post="cell lines. It showed percent of cell growth promotion"/>
  <result pre="cell lines. It showed percent of cell growth promotion for" exact="colon cancer" post="HCT-116, leukaemia K-562, non-small cell lung cancer HOP-92, and"/>
  <result pre="lines. It showed percent of cell growth promotion for colon" exact="cancer" post="HCT-116, leukaemia K-562, non-small cell lung cancer HOP-92, and"/>
  <result pre="growth promotion for colon cancer HCT-116, leukaemia K-562, non-small cell" exact="lung cancer" post="HOP-92, and colon cancer HT29 of 61.10%, 58.92%, 57.13%,"/>
  <result pre="promotion for colon cancer HCT-116, leukaemia K-562, non-small cell lung" exact="cancer" post="HOP-92, and colon cancer HT29 of 61.10%, 58.92%, 57.13%,"/>
  <result pre="cancer HCT-116, leukaemia K-562, non-small cell lung cancer HOP-92, and" exact="colon cancer" post="HT29 of 61.10%, 58.92%, 57.13%, and 20.27%, respectively (cell"/>
  <result pre="HCT-116, leukaemia K-562, non-small cell lung cancer HOP-92, and colon" exact="cancer" post="HT29 of 61.10%, 58.92%, 57.13%, and 20.27%, respectively (cell"/>
  <result pre="inÂ vitro anticancer activity against full 60 lines of human" exact="cancer" post="cells. VEGFR-2 enzyme inhibitory assay was performed to investigate"/>
  <result pre="reported by the author(s). References References 1VarmusH.The new era in" exact="cancer" post="research. Science2006;312:1162â€&quot;5.16728627 2GibbsJB.Mechanism-based target identification and drug discovery in"/>
  <result pre="cancer research. Science2006;312:1162â€&quot;5.16728627 2GibbsJB.Mechanism-based target identification and drug discovery in" exact="cancer" post="research. Science2000;287:1969â€&quot;73.10720316 3KerruN, SinghP, KoorbanallyN, et al.Recent advances (2015â€&quot;2016)"/>
  <result pre="Eur J Med Chem2017;142:179â€&quot;212.28760313 4GerberDE.Targeted therapies: a new generation of" exact="cancer" post="treatments. Am Fam Phys2008;77:311â€&quot;9. 5KerbelRS.Tumor angiogenesis: past, present and"/>
  <result pre="ChristoforiG.The angiogenic switch in carcinogenesis. Semin Cancer Biol2009;19:329â€&quot;37.19482086 8FidlerIJ.Angiogenesis and" exact="cancer" post="metastasis. Cancer J2000;6:S134â€&quot;S41.10803828 9ShawverLK, LipsonKE, FongTAT, et al.Receptor tyrosine"/>
  <result pre="of angiogenesis. Drug Discov Today1997;2:50â€&quot;63. 10TraxlerP.Tyrosine kinases as targets in" exact="cancer" post="therapy â€&quot; successes and failures. Expert Opin Ther Targets2003;7:215â€&quot;34.12667099"/>
  <result pre="between type I and type II binding modes of anaplastic" exact="lymphoma" post="kinase (ALK). J Med Chem2016;59:3906â€&quot;19.27031565 37ThomasR, MaryYS, ResmiKS, et"/>
  <result pre="converting enzyme (ACE) inhibitors. Bioorg Med Chem2011;19:4772â€&quot;81.21782455 43RomagnoloDF, SelminOI.Flavonoids and" exact="cancer" post="prevention: a review of the evidence. J Nutr Gerontol"/>
  <result pre="al.The novel oxygenated chalcone, 2,4-dimethoxy-4â€²-butoxychalcone, exhibits potent activity against human" exact="malaria" post="parasite Plasmodium falciparum inÂ vitro and rodent parasites Plasmodium"/>
  <result pre="45WinterE, GozziGJ, Chiaradia-DelatorreLD, et al.Quinoxaline-substituted chalcones as new inhibitors of" exact="breast cancer" post="resistance protein ABCG2: polyspecificity at B-ring position. Drug Des"/>
  <result pre="GozziGJ, Chiaradia-DelatorreLD, et al.Quinoxaline-substituted chalcones as new inhibitors of breast" exact="cancer" post="resistance protein ABCG2: polyspecificity at B-ring position. Drug Des"/>
  <result pre="et al.Prenylflavone derivatives from Broussonetia papyrifera, inhibit the growth of" exact="breast cancer" post="cells inÂ vitro and inÂ vivo. Phytochem Lett2013;6:331â€&quot;6. 50SiskoJT,"/>
  <result pre="al.Prenylflavone derivatives from Broussonetia papyrifera, inhibit the growth of breast" exact="cancer" post="cells inÂ vitro and inÂ vivo. Phytochem Lett2013;6:331â€&quot;6. 50SiskoJT,"/>
 </snippets>
</snippetsTree>
